A new treatment for mesothelioma was recently given orphan drug status by the United States FDA. The company given orphan drug status is known as Avenge Bio, which is a biotechnology company working to create a new immunotherapy treatment regimen. It announced that it was given orphan drug status back[…]
Latest Immunotherapy Treatments
PARP Inhibitors Could Soon Help Mesothelioma Patients
There is a new treatment involving PARP inhibitors that could potentially benefit mesothelioma patients. PARP stands for Poly (ADP-ribose) polymerase. PARP is typically involved in repairing damaged DNA in cells. It can be useful against side effects from chemotherapy by repairing damaged tumor cells, which helps tumors to continue growing.[…]
Galinpepimut-S and Nivolumab are Effective and Safe for Mesothelioma
The combination of galinpepimut-S and nivolumab is showing promising results for mesothelioma. The study looked at patients who were refractory or relapsed after at least one standard treatment. The combination met safety and efficacy standards for treatment, leading to a completed phase one trial. The median overall survival, which was[…]
Pembrolizumab and Chemotherapy Improve Survival in Pleural Mesothelioma Patients
The mix of chemotherapy and pembrolizumab extended survival in patients with pleural mesothelioma. It was given as a first line treatment to adults with the cancer. Data shows that pembrolizumab and chemotherapy reduced death by 21 percent compared to chemotherapy alone. Doctors like the combination of pembrolizumab and chemotherapy because[…]
Researchers Tried to Determine Which Second Line Treatment is Best for Mesothelioma
Researchers from China tried to determine whether immunotherapy or chemotherapy is better as a second line treatment option for relapsed pleural mesothelioma. There is no current standard therapy for people whose mesothelioma comes back, which makes it hard for doctors to make treatment decisions for patients. Mesothelioma is very aggressive,[…]
YAP/TEAD Inhibitor is Showing Promising Results for Mesothelioma and NF2-Mutant Cancers
A YAP/TEAD inhibitor is showing promising results for people with mesothelioma and other cancers. The inhibitor, known as VT3989, was well tolerated and had good anti-tumor effects in cancer patients with mesothelioma and NF2 mutations. Results were recently published from the first human study. Seven of 69 patients had radiological[…]
Keytruda Helps Improve Survival for Mesothelioma When Used Alongside Chemotherapy
Keytruda is showing promising results for the treatment of pleural mesothelioma. Researchers found that the combination of Keytruda (pembrolizumab) and chemotherapy lead to a better survival in patients versus chemotherapy alone. Mesothelioma is a hard-to-treat cancer with no cure. It can be found in the linings of the lungs, abdomen,[…]
A Vaccine to Prevent and Treat Mesothelioma Could be Possible in the Future
A vaccine for lung cancer could possibly lead to a vaccine for mesothelioma. The lung cancer immunotherapy drug CIMAvax-EFG is making great progress, and because of this progress, researchers are utilizing the treatment in new ways. The researchers are trying to see how the vaccine can be used to prevent[…]
Cytokine Factories to Treat Pleural and Peritoneal Mesothelioma
A new study from Rice University in Houston is showing promising results for mesothelioma. It utilizes the immune system to fight cancer cells. The protein that is being studied is interleukin 2 (IL2), which is a protein that regulates white blood cells through the use of cytokines, a cell signal[…]
Opdivo and Yervoy After Mesothelioma Surgery Improves Survival
There might be more options for treating mesothelioma. A study looked at the combination of Opdivo and Yervoy after surgery. The study was performed at the Hyogo College of Medicine in Japan. Opdivo and Yervoy, which were recently approved for the treatment of mesothelioma, improved survival when administered after surgery.[…]
